Format

Send to

Choose Destination
Nat Rev Genet. 2014 Aug;15(8):541-55. doi: 10.1038/nrg3763. Epub 2014 Jul 15.

Non-viral vectors for gene-based therapy.

Author information

1
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02142, USA.
2
1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02142, USA. [2] Department of Chemical Engineering, MIT, Cambridge, Massachusetts 02142, USA.
3
1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02142, USA. [2] Department of Anesthesiology, Children's Hospital Boston, Boston, Massachusetts 02115, USA.
4
1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02142, USA. [2] Department of Biology, MIT, Cambridge, Massachusetts 02142, USA.
5
1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02142, USA. [2] Department of Chemical Engineering, MIT, Cambridge, Massachusetts 02142, USA. [3] Department of Anesthesiology, Children's Hospital Boston, Boston, Massachusetts 02115, USA. [4] Harvard-MIT Division of Health Sciences & Technology, MIT, Cambridge, Massachusetts 02139, USA. [5] Institute for Medical Engineering and Science, MIT, Cambridge, Massachusetts 02142, USA.

Abstract

Gene-based therapy is the intentional modulation of gene expression in specific cells to treat pathological conditions. This modulation is accomplished by introducing exogenous nucleic acids such as DNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides. Given the large size and the negative charge of these macromolecules, their delivery is typically mediated by carriers or vectors. In this Review, we introduce the biological barriers to gene delivery in vivo and discuss recent advances in material sciences, nanotechnology and nucleic acid chemistry that have yielded promising non-viral delivery systems, some of which are currently undergoing testing in clinical trials. The diversity of these systems highlights the recent progress of gene-based therapy using non-viral approaches.

PMID:
25022906
DOI:
10.1038/nrg3763
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center